搜索优化
Rewards
English
搜索
Copilot
图片
视频
地图
资讯
购物
更多
航班
旅游
酒店
房地产
笔记本
Top stories
Sports
U.S.
Local
World
Science
Technology
Entertainment
Business
More
Politics
时间不限
过去 1 小时
过去 24 小时
过去 7 天
过去 30 天
按相关度排序
按时间排序
centerforbiosimilars
7 小时
IRA Reimbursement Impact on Biosimilars Minimal Despite Rising Market Share
The Inflation Reduction Act (IRA) has modestly boosted oncology biosimilar uptake through Medicare reimbursement, but its ...
centerforbiosimilars
1 天
AAM Report: Despite Massive Savings, Patient OOP Costs on Biosimilars, Generics Remain High ...
Part 2 of our series diving into the Association for Accessible Medicines' (AAM) latest report discusses that while generics ...
centerforbiosimilars
1 天
BioRationality—The Missing Rationality in Biosimilar Discussions and the Path Forward
The article by Sarfaraz K. Niazi, PhD, critiques the irrationality surrounding biosimilars, suggesting that regulatory ...
centerforbiosimilars
1 天
Skylar Jeremias
Part 2 of our series diving into the Association for Accessible Medicines' (AAM) latest report discusses that while generics and biosimilars saved $445 billion in 2023, their potential is hindered by ...
centerforbiosimilars
7 天
AAM Report: Generics and Biosimilars Savings Reach $445 Billion in 2023, Part 1
Savings from generic and biosimilar drugs totaled $445 billion in 2023, showing promise for the growth of both markets and ...
centerforbiosimilars
5 天
The Top 5 Biosimilar Articles for the Week of September 16
Number 5: The FDA has approved Pavblu (aflibercept-ayyh), the fifth biosimilar referencing Eylea (aflibercept).1 The new ...
centerforbiosimilars
10 天
STADA Credits Biosimilar Expansion for Profitable First Half of 2024
German biosimilar manufacturer STADA Arzneimittel reported a 9% revenue increase in the first half of 2024, with over €2 ...
centerforbiosimilars
8 天
Expanding Biosimilar Adoption: Insights and Strategies With Dr Sophia Humphreys
Sophia Humphreys, PharmD, MHA, BCBBS, director of system formulary management at Sutter Health, discusses the challenges of ...
centerforbiosimilars
15 天
Patients With nAMD Successfully Switch From Aflibercept to Ranibizumab
A study found patients with neovascular age-related macular degeneration (nAMD) successfully switched from aflibercept to the ...
centerforbiosimilars
8 天
FDA Approves Pavblu for Retinal Conditions
Amgen’s Pavblu (aflibercept-ayyh) is the fifth biosimilar referencing Eylea (aflibercept) to be approved for American ...
centerforbiosimilars
14 天
The Future of Biosimilar Gene Therapies: Key Issues and Potential
While biosimilars could potentially lower costs and improve access to gene therapies, significant hurdles in regulation, ...
centerforbiosimilars
16 天
BioRationality: FDA Clarification Provides New Indications and Process Change for Biosimilars
Sarfaraz K. Niazi, PhD, explains the FDA's new guidelines on post-approval changes for biosimilars, emphasizing the processes ...
一些您可能无法访问的结果已被隐去。
显示无法访问的结果
反馈